CNCR vs. SMH

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and SMH (VanEck Semiconductor ETF) are both exchange-traded funds - CNCR is a Health & Biotech Equities fund tracking the Loncar Cancer Immunotherapy Index, while SMH is a Semiconductors fund tracking the MVIS US Listed Semiconductor 25 Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.35%/yr for SMH.

Performance

CNCR vs. SMH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and VanEck Semiconductor ETF (SMH). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

SMH

• 1D: 4.01%
• 1M: 24.01%
• YTD: 75.55%
• 6M: 76.44%
• 1Y: 160.66%
• 3Y*: 63.68%
• 5Y*: 39.58%
• 10Y*: 37.55%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. SMH - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
SMH VanEck Semiconductor ETF	57.40%

CNCR vs. SMH - Sectors Allocation Comparison

Sectors	CNCR	SMH
Healthcare	96.6%	-
Financial Services	3.3%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	100.0%
Utilities	-	-

Return for Risk

CNCR vs. SMH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SMH

SMH Risk / Return Rank: 96
SMH Sharpe Ratio Rank: 98
SMH Sortino Ratio Rank: 95
SMH Omega Ratio Rank: 95
SMH Calmar Ratio Rank: 97
SMH Martin Ratio Rank: 97

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. SMH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and VanEck Semiconductor ETF (SMH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	SMH	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	5.29	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	1.14	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.16	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.34	—

Drawdowns

CNCR vs. SMH - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum SMH drawdown of -84.96%. Use the drawdown chart below to compare losses from any high point for CNCR and SMH.

Drawdown Indicators

	CNCR	SMH	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-84.96%	+84.96%
Max Drawdown (1Y) Largest decline over 1 year	—	-14.93%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-35.74%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-45.30%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-45.30%	—
Current Drawdown Current decline from peak	0.00%	0.00%	0.00%
Average Drawdown Average peak-to-trough decline	0.00%	-41.09%	+41.09%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	3.89%	—

Volatility

Volatility by Period

	CNCR	SMH	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	11.59%	—
Volatility (6M) Calculated over the trailing 6-month period	—	24.29%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	30.57%	-30.57%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	35.02%	-35.02%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	32.58%	-32.58%

CNCR vs. SMH - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than SMH's 0.35% expense ratio.

Dividends

CNCR vs. SMH - Dividend Comparison

CNCR has not paid dividends to shareholders, while SMH's dividend yield for the trailing twelve months is around 0.17%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SMH VanEck Semiconductor ETF	0.17%	0.31%	0.44%	0.60%	1.18%	0.51%	0.69%	1.50%	1.88%	1.43%	0.80%	2.14%

Frequently Asked Questions

Which ETF is better, CNCR or SMH?

On fees, SMH is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or SMH?

SMH is cheaper with a 0.35% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or SMH?

SMH has the higher dividend yield at 0.17%, compared with 0.00% for CNCR.

What is the main difference between CNCR and SMH?

CNCR is categorized as Health & Biotech Equities, while SMH is Semiconductors. CNCR tracks Loncar Cancer Immunotherapy Index, while SMH tracks MVIS US Listed Semiconductor 25 Index. They also come from different issuers: Exchange Traded Concepts and VanEck. Their fees differ too: 0.79% for CNCR and 0.35% for SMH.